Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $35
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to $35.
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to $35.